title: [Evaluation of postoperative analgesia with continuous iliofascial nerve sheath block after total hip arthroplasty replacement: a pilot study].
abstract: OBJECTIVE
  To assess the analgesic efficiency of a continuous iliofascial nerve sheath block after total hip arthroplasty replacement (RPTH).
  
  
  METHODS
  open and prospective pilot study.
  
  
  METHODS
  Before induction of general anaesthesia (GA), an iliofascial catheter was inserted (group KT, n = 11) or not (group NKT, n = 10). In the KT group, 30 ml of ropivacaïne 4,75 mg/ml (maximum dose) were injected, and 14 mg/h of ropivacaïne 2 mg/ml were infused during the first 48 postoperative hours. All patients underwent a standardized GA and a multimodal postoperative analgesia with a intravenous PCA morphine, paracetamol and tramadol during the first 48 hours. Postoperative pain assessment which was achieved using visual analogic scores (VAS) at rest (EVAr) and on movement (EVAm), total morphine consumption, and side effects were collected during the first 48 hours. Statistical analysis was performed using a Mann and Whitney test for the quantitative values and a chi 2 exact test for the qualitative values. Data are expressed as median [interquartile range].
  
  
  RESULTS
  Total morphine consumption was lower in the KT group with a total amount of 26 mg [11-48] versus 77.5 mg [55-91] (p = 0.007) at h48. EVAr and EVAm were lower in the KT group at h4, h8, h24, h36 for the EVAr and during the 48 postoperative hours for EVAm. Three patients experienced nausea and/or vomiting in the KT group versus 6 in the NKT group (p = 0.05).
  
  
  CONCLUSIONS
  After RPTH surgery, continuous iliofascial block reduces morphine consumption; provide a better pain relief at rest and on movement than IV multimodal analgesia alone.
authors.affiliation: Département d'anesthésie-réanimation et Samu, CHU Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France.
authors.forename: E
authors.initials: E
authors.lastname: Pavy
authors.forename: V
authors.initials: V
authors.lastname: Compère
authors.forename: V
authors.initials: V
authors.lastname: Fourdrinier
authors.forename: C-E
authors.initials: CE
authors.lastname: Beghin
authors.forename: F
authors.initials: F
authors.lastname: Dujardin
authors.forename: B
authors.initials: B
authors.lastname: Dureuil
mesh_terms: D000082:Acetaminophen / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000008:administration & dosage / Q000627:therapeutic use*; D016058:Analgesia, Patient-Controlled; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D002404:Catheterization; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use; D009325:Nausea / Q000209:etiology; D009407:Nerve Block / Q000379:methods*; D010149:Postoperative Pain / Q000628:therapy*; D017060:Patient Satisfaction; D010865:Pilot Projects; D011182:Postoperative Care / Q000379:methods*; D011183:Postoperative Complications / Q000209:etiology; D011446:Prospective Studies; D000077212:Ropivacaine; D014147:Tramadol / Q000008:administration & dosage / Q000627:therapeutic use; D016055:Urinary Retention / Q000209:etiology; D014839:Vomiting / Q000209:etiology
chemical_list: D000577:Amides; D018712:Analgesics, Non-Narcotic; D000082:Acetaminophen; D014147:Tramadol; D009020:Morphine; D000077212:Ropivacaine